Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Consensus PT from Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has received a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $41.00.

ELVN has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,500 shares of the stock in a transaction on Monday, October 20th. The stock was sold at an average price of $22.08, for a total value of $276,000.00. Following the completion of the transaction, the insider owned 915,188 shares in the company, valued at approximately $20,207,351.04. This represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $17.40, for a total value of $116,005.80. Following the completion of the sale, the chief operating officer directly owned 269,974 shares of the company’s stock, valued at approximately $4,697,547.60. This trade represents a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 74,997 shares of company stock valued at $1,568,769. Corporate insiders own 25.90% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its holdings in shares of Enliven Therapeutics by 61.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after acquiring an additional 80,506 shares during the period. Affinity Asset Advisors LLC purchased a new stake in Enliven Therapeutics during the second quarter worth $8,024,000. Geode Capital Management LLC grew its holdings in Enliven Therapeutics by 7.8% in the second quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock valued at $17,711,000 after purchasing an additional 63,580 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Enliven Therapeutics by 2,029.3% in the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after buying an additional 410,034 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Enliven Therapeutics by 39.6% during the 1st quarter. Invesco Ltd. now owns 21,044 shares of the company’s stock worth $414,000 after buying an additional 5,972 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $15.54 on Friday. Enliven Therapeutics has a one year low of $13.30 and a one year high of $25.37. The stock has a market capitalization of $922.30 million, a price-to-earnings ratio of -8.45 and a beta of 0.41. The company has a 50-day simple moving average of $19.43 and a 200-day simple moving average of $20.02.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. As a group, research analysts forecast that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.